TY - JOUR
T1 - A stacking ensemble machine learning model for evaluating cardiac toxicity of drugs based on in silico biomarkers
AU - Fuadah, Yunendah Nur
AU - Qauli, Ali Ikhsanul
AU - Pramudito, Muhammad Adnan
AU - Marcellinus, Aroli
AU - Hanum, Ulfa Latifa
AU - Lim, Ki Moo
N1 - Publisher Copyright:
© 2024 The Author(s). CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
PY - 2024
Y1 - 2024
N2 - This study addresses the critical issue of drug-induced torsades de pointes (TdP) risk assessment, a vital aspect of new drug development due to its association with arrhythmia and sudden cardiac death. Existing methodologies, particularly those reliant on a single biomarker derived from CiPA O'Hara-Rudy (CiPAORdv1.0) ventricular cell model without the hERG dynamic as input to the individual machine learning model, have limitations in capturing the complexity inherent in the comprehensive range of factors influencing drug-induced TdP risk. This study aims to overcome these limitations by proposing a stacking ensemble machine learning approach by integrating multiple in silico biomarkers derived from the CiPAORdv1.0 with hERG dynamic characteristics. The ensemble machine learning model consisted of three artificial neural network (ANN) models as baseline model and support vector machine (SVM), logistic regression (LR), random forest (RF), and extreme gradient boosting (XGBoost) models as meta-classifier. The highest AUC score of 1.00 (0.90–1.00) for high risk, 0.97 (0.84–1.00) for intermediate risk, and 1.00 (0.87–1.00) for low risk were obtained using seven biomarkers derived from the CiPAORdv1.0 with hERG dynamic characteristics. Furthering our investigation, we explored the model's robustness by incorporating interindividual variability into the generation of in silico biomarkers from a population of human ventricular cell models. This study also enabled an analysis of TdP risk classification under high clinical exposure and therapeutic scenarios for several drugs. Additionally, from a sensitivity analysis, we revealed four important ion channels, namely, CaL, NaL, Na, and Kr channels that affect significantly the important biomarkers for TdP risk prediction.
AB - This study addresses the critical issue of drug-induced torsades de pointes (TdP) risk assessment, a vital aspect of new drug development due to its association with arrhythmia and sudden cardiac death. Existing methodologies, particularly those reliant on a single biomarker derived from CiPA O'Hara-Rudy (CiPAORdv1.0) ventricular cell model without the hERG dynamic as input to the individual machine learning model, have limitations in capturing the complexity inherent in the comprehensive range of factors influencing drug-induced TdP risk. This study aims to overcome these limitations by proposing a stacking ensemble machine learning approach by integrating multiple in silico biomarkers derived from the CiPAORdv1.0 with hERG dynamic characteristics. The ensemble machine learning model consisted of three artificial neural network (ANN) models as baseline model and support vector machine (SVM), logistic regression (LR), random forest (RF), and extreme gradient boosting (XGBoost) models as meta-classifier. The highest AUC score of 1.00 (0.90–1.00) for high risk, 0.97 (0.84–1.00) for intermediate risk, and 1.00 (0.87–1.00) for low risk were obtained using seven biomarkers derived from the CiPAORdv1.0 with hERG dynamic characteristics. Furthering our investigation, we explored the model's robustness by incorporating interindividual variability into the generation of in silico biomarkers from a population of human ventricular cell models. This study also enabled an analysis of TdP risk classification under high clinical exposure and therapeutic scenarios for several drugs. Additionally, from a sensitivity analysis, we revealed four important ion channels, namely, CaL, NaL, Na, and Kr channels that affect significantly the important biomarkers for TdP risk prediction.
UR - http://www.scopus.com/inward/record.url?scp=85202014505&partnerID=8YFLogxK
U2 - 10.1002/psp4.13229
DO - 10.1002/psp4.13229
M3 - Article
AN - SCOPUS:85202014505
SN - 2163-8306
JO - CPT: Pharmacometrics and Systems Pharmacology
JF - CPT: Pharmacometrics and Systems Pharmacology
ER -